Abstract
This editorial comments on a study by Zuo et al. The focus is on the efficacy of hepatic arterial infusion chemotherapy combined with camrelizumab and apatinib (the TRIPLET regimen), alongside microwave ablation therapy, in treating advanced hepatocellular carcinoma (HCC). The potential application of this combination therapy for patients with advanced HCC is evaluated.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have